Epimedium sagittatum (Epimedium sagittatum): Benefits, Dosage, Safety & Evidence

Questions fréquentes

How does Epimedium sagittatum work for erectile dysfunction?

Epimedium sagittatum works primarily through its active compound icariin, which functions as a phosphodiesterase type 5 (PDE5) inhibitor. This mechanism increases levels of cyclic guanosine monophosphate (cGMP), relaxing smooth muscle tissue and increasing blood flow to the genital area. Additionally, the herb exhibits estrogenic effects that may influence hormonal balance. Evidence for this mechanism is rated Level C, derived largely from in vitro and animal studies rather than extensive human clinical trials.

Does Epimedium sagittatum interact with medications?

Yes, Epimedium sagittatum has significant interaction potential. Due to its estrogenic properties, it may interfere with hormone replacement therapies and birth control medications. Because icariin affects blood clotting, it can potentiate the effects of anticoagulants like warfarin, increasing bleeding risk. Furthermore, combining it with prescription PDE5 inhibitors may cause additive effects and hypotension. Patients taking these medications should consult a healthcare provider before use.

What is the recommended dosage for Epimedium sagittatum?

Adult dosages vary depending on the formulation. For standardized extracts, the typical recommendation is 500 to 1000 mg taken twice daily. Traditional preparations using the dried herb generally utilize 6 to 15 grams per day, often decocted in water. Dosage should be adjusted based on the specific icariin concentration of the product. Users should follow manufacturer guidelines or consult a qualified medical herbalist for personalized dosing.

Is Epimedium sagittatum safe during pregnancy?

No, Epimedium sagittatum is contraindicated during pregnancy and is considered unsafe. The herb exerts significant hormonal effects, including estrogenic activity, which can disrupt the delicate hormonal balance required for fetal development and pregnancy maintenance. These properties pose a risk of miscarriage or fetal complications. Breastfeeding women should also avoid this herb. Women with hormone-sensitive conditions, such as breast or ovarian cancer, must strictly avoid this supplement.

Can Epimedium sagittatum improve bone health?

Research suggests potential benefits for bone health, particularly regarding osteoporosis. Preclinical studies indicate that icariin can stimulate osteoblast differentiation and inhibit osteoclast activity, thereby promoting bone formation and reducing bone resorption. While these mechanisms are promising for managing bone loss, current evidence is rated Level C, relying primarily on animal models. Well-designed human clinical trials are necessary to confirm efficacy and establish therapeutic protocols for bone conditions.

Fiche d'information compilée à partir de PubMed

Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.

Compilé à partir de 30 articles PubMed · modèle : gemma4:31b

Résumé

Epimedium sagittatum is a traditional medicinal plant used primarily in Asia to treat erectile dysfunction and kidney-Yang deficiency [PMID:38593963, PMID:23792897]. Its primary bioactive components are flavonoids, which exhibit various pharmacological activities including anti-inflammatory and PDE5A inhibitory effects [PMID:36863569, PMID:30424767].

Contexte

Epimedium sagittatum (Sieb. et Zucc.) Maxim is a member of the Berberidaceae family and a perennial traditional Chinese medicinal herb [PMID:33365631, PMID:27733858]. It is characterized by a relatively large haploid genome of approximately 4496 Mbp [PMID:23807511].

Usages traditionnels

Traditionally used in Asia to dispel wind and cold, tonify the kidney, strengthen bones and tendons [PMID:38593963], and treat erectile dysfunction, impotence, and rheumatism [PMID:23792897, PMID:33691203].

Composés actifs

The main active ingredients are flavonoids, specifically icariin, epimedin A, epimedin B, and epimedin C [PMID:36837913, PMID:36471925]. Other identified compounds include 2''-O-rhamnosyl icariside II [PMID:40812555], baohuoside I [PMID:3658722 la, PMID:41380862], and various prenylated flavonoids such as epimesatines A-S [PMID:35810878, PMID:39407639].

Mécanisme d'action

The herb acts through several pathways: inhibition of phosphodiesterase-5A (PDE5A) to treat erectile dysfunction [PMID:36863569, PMID:41380862], inhibition of the TLR4/MD-2 mediated NF-κB signaling pathway for anti-inflammatory effects [PMID:30424767, PMID:41432450], and modulation of the PI3K/AKT signaling pathway to restrain inflammation and apoptosis [PMID:37382268].

Preuves cliniques

Preuve BGulf War Illness (GWI)

Symptom severity was unchanged from placebo in a pseudo-randomized crossover trial [PMID:33915962]

Preuve DPulmonary Fibrosis

Aqueous extract and the compound 2''-O-rhamnosyl icariside II ameliorated pulmonary fibrosis in mouse models [PMID:40812555, PMID:38114154]

Preuve DAdriamycin-induced nephropathy

Ameliorated nephropathy by restraining inflammation and apoptosis via the PI3K/AKT pathway in rats [PMID:37382268]

Preuve DSepsis-Associated Acute Kidney Injury (S-AKI)

Exosome-like nanovesicles (ENVs) from E. sagittatum ameliorated renal injury in murine models by reshaping gut microbiota and suppressing the TLR4/NF-κB pathway [PMID:41432450]

Preuve DBreast Cancer (MCF-7 cells)

Epimesatines P-S exhibited significant inhibitory effects on the viability of MCF-7 human breast cancer cells in vitro [PMID:39407639]

Preuve DNon-small cell lung cancer (A549 cells)

Sécurité et effets indésirables

Aqueous extracts have been shown to induce liver injury in mice via pyroptosis [PMID:38593963]. Sub-chronic toxicity studies in rats indicated potential injury to the liver, pancreas, and adrenal glands, as well as dysregulation of amino acid biosynthesis [PMID:35287533].

Interactions médicamenteuses

Significant herb-drug interactions were observed in rats; E. sagittatum extract significantly decreased the area under the concentration-time curve (AUC) of sildenafil [PMID:23792897].

Synthèse des preuves

The evidence consists primarily of in vitro studies and animal models (Level D), with one pseudo-randomized clinical trial (Level B) showing no significant effect on Gulf War Illness symptoms. While pharmacological potential is noted for kidney and lung conditions, safety concerns regarding liver toxicity in animals have been reported.

Sources PubMed

1.PMID: 36837913 (2023) — A Comprehensive Analysis to Elucidate the Effects of Spraying Mineral Elements on the Accumulation of Flavonoids in Epimedium sagittatum during the Harvesting Period. · Metabolites
2.PMID: 38593963 (2024) — Aqueous extract of Epimedium sagittatum (Sieb. et Zucc.) Maxim. induces liver injury in mice via pyroptosis. · Journal of ethnopharmacology
3.PMID: 23792897 (2013) — Herb-drug interaction of Epimedium sagittatum (Sieb. et Zucc.) maxim extract on the pharmacokinetics of sildenafil in rats. · Molecules (Basel, Switzerland)
4.PMID: 36863569 (2023) — Flavonoids and prenylhydroquinones from the prepared folium of Epimedium sagittatum Maxim. and their inhibition against phosphodiesterase5A. · Fitoterapia
5.PMID: 40812555 (2025) — 2″-O-rhamnosyl icariside Ⅱ from Epimedium sagittatum maxim ameliorates pulmonary fibrosis by modulating the E-cadherin-mediated oxidative-epithelial mesenchymal transition axis.

Epimedium sagittatum

Sources et citations

Calculer une dose sûre de Epimedium sagittatum